GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vivesto AB (OTCPK:OASMY) » Definitions » Capex-to-Operating-Income

OASMY (Vivesto AB) Capex-to-Operating-Income : 0.00 (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Vivesto AB Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Vivesto AB's Capital Expenditure for the three months ended in Mar. 2025 was $-0.59 Mil. Its Operating Income for the three months ended in Mar. 2025 was $-0.85 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Vivesto AB Capex-to-Operating-Income Historical Data

The historical data trend for Vivesto AB's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivesto AB Capex-to-Operating-Income Chart

Vivesto AB Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Vivesto AB Quarterly Data
Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vivesto AB's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Vivesto AB's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivesto AB's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vivesto AB's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Vivesto AB's Capex-to-Operating-Income falls into.


;
;

Vivesto AB Capex-to-Operating-Income Calculation

Vivesto AB's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -3.82
=N/A

Vivesto AB's Capex-to-Operating-Income for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.594) / -0.848
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vivesto AB  (OTCPK:OASMY) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Vivesto AB Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Vivesto AB's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivesto AB Business Description

Traded in Other Exchanges
Address
Gustav III:s Boulevard 46, 5th Floor, Solna, SWE, SE-169 73
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.

Vivesto AB Headlines

From GuruFocus

Q3 2022 Vivesto AB Earnings Call Transcript

By GuruFocus Research 03-06-2024

Oasmia Pharmaceutical AB (publ) - Special Call Transcript

By GuruFocus Research 03-06-2024

Q3 2021 Oasmia Pharmaceutical AB Earnings Call Transcript

By GuruFocus Research 03-06-2024

Q2 2021 Oasmia Pharmaceutical AB Earnings Call Transcript

By GuruFocus Research 03-06-2024

Q1 2021 Oasmia Pharmaceutical AB Earnings Call Transcript

By GuruFocus Research 03-06-2024